Phase 2 Retinitis Pigmentosa Clinical Trials
11 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–11 of 11 trials
Recruiting
Phase 2
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Retinitis Pigmentosa
Kiora Pharmaceuticals, Inc.36 enrolled5 locationsNCT06628947
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
Retinitis Pigmentosa
Sumitomo Pharma America, Inc.12 enrolled2 locationsNCT06891885
Recruiting
Phase 2
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
Retinitis Pigmentosa
jCyte, Inc60 enrolled14 locationsNCT06912633
Recruiting
Phase 2
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
X-Linked Retinitis Pigmentosa (XLRP)
Beacon Therapeutics10 enrolled6 locationsNCT07174726
Recruiting
Phase 1Phase 2
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
Retinitis Pigmentosa
Octant, Inc.50 enrolled1 locationNCT07408232
Recruiting
Phase 1Phase 2
BS01 in Patients With Retinitis Pigmentosa
Retinitis Pigmentosa
Bionic Sight LLC20 enrolled1 locationNCT04278131
Recruiting
Phase 1Phase 2
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting
Phase 1Phase 2
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Retinitis PigmentosaChoroideremiaNon-Syndromic Rod-Dominant Inherited Retinal Diseases
Kiora Pharmaceuticals, Inc.48 enrolled3 locationsNCT05282953
Recruiting
Phase 1Phase 2
Promising ROd-cone DYstrophy Gene therapY
Retinitis Pigmentosa
SparingVision33 enrolled6 locationsNCT05748873
Recruiting
Phase 1Phase 2
Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa
Retinitis Pigmentosa
Mahidol University15 enrolled1 locationNCT06242379
Recruiting
Phase 1Phase 2
Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa
X-Linked Retinitis Pigmentosa (XLRP)
Frontera Therapeutics32 enrolled1 locationNCT06492850